| 林 铃,程 虹,韩 柳,冯彩霞,常 乐.宫炎康胶囊联合头孢他啶对慢性盆腔炎患者血清炎症因子、血液流变学及生存质量的影响[J].,2021,(16):3196-3200 |
| 宫炎康胶囊联合头孢他啶对慢性盆腔炎患者血清炎症因子、血液流变学及生存质量的影响 |
| Effect of Gongyankang Capsule Combined with Ceftazidime on Serum Inflammatory Factors, Hemorheology and Quality of Life in Patients with Chronic Pelvic Inflammatory Disease |
| 投稿时间：2021-01-14 修订日期：2021-02-10 |
| DOI：10.13241/j.cnki.pmb.2021.16.040 |
| 中文关键词: 宫炎康胶囊 头孢他啶 慢性盆腔炎 炎症因子 血液流变学 生存质量 |
| 英文关键词: Gongyankang capsule Ceftazidime Chronic pelvic inflammatory disease Inflammatory factors Hemorheology Quality of life |
| 基金项目:海南省卫生计生行业科研基金项目(16A200006) |
|
| 摘要点击次数: 730 |
| 全文下载次数: 419 |
| 中文摘要: |
| 摘要 目的：探讨宫炎康胶囊联合头孢他啶对慢性盆腔炎患者血清炎症因子、血液流变学及生存质量的影响。方法：选取2018年3月~2020年7月期间我院收治的慢性盆腔炎患者98例，根据信封抽签法将患者分为对照组和观察组，两组各为49例。对照组给予头孢他啶治疗，观察组在对照组的基础上联合宫炎康胶囊治疗，均连续治疗2周。对比两组疗效、临床症状消失时间、血清炎症因子、血液流变学、生存质量及不良反应。结果：观察组的临床总有效率高于对照组（P<0.05）。观察组下腹疼痛、腰骶胀痛、带下异常消失时间短于对照组（P<0.05）。治疗2周后，两组血清白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、C-反应蛋白（CRP）水平均下降，且观察组低于对照组（P<0.05）。治疗2周后，两组高切全血比粘度、低切全血比粘度、血浆比粘度均下降，且观察组低于对照组（P<0.05）。治疗2周后，两组心理健康、生理健康、周围环境、社会关系评分均升高，且观察组高于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：头孢他啶与宫炎康胶囊联合治疗慢性盆腔炎，可缓解炎症反应，改善患者血液流变学及生存质量，安全有效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Gongyankang capsule combined with ceftazidime on serum inflammatory factors, hemorheology and quality of life in patients with chronic pelvic inflammatory disease. Methods: 98 patients with chronic pelvic inflammatory disease who were admitted to our hospital from March 2018 to July 2020 were selected, and divided into control group and observation group according to envelope drawing method, with 49 cases in each group. The control group was treated with ceftazidime, and the observation group was treated with Gongyankang capsule on the basis of the control group, all patients were treated for 2 weeks. The curative effect, disappearance time of clinical symptoms, serum inflammatory factors, hemorheology, quality of life and adverse reactions were compared between the two groups. Results: The clinical total effective rate of the observation group was higher than that of the control group (P<0.05). The disappearance time of clinical symptoms such as lower abdominal pain, lumbosacral distending pain and abnormal band of the observation group were shorter than those of the control group(P<0.05). 2 weeks after treatment, the serum levels of interleukin-6(IL-6), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP) of the two groups decreased, and the observation group was lower than the control group (P<0.05). 2 weeks after treatment, the high shear whole blood specific viscosity, low shear whole blood specific viscosity and plasma specific viscosity of the two groups decreased, and the observation group was lower than the control group (P<0.05). 2 weeks after treatment, the scores of mental health, physical health, surrounding environment and social relations of the two groups were increased, and the observation group was higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Gongyankang capsule combined with ceftazidime in the treatment of chronic pelvic inflammatory disease can alleviate inflammatory reaction, improve hemorheology and quality of life of patients, which is safe and effective. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
